Muscle & Nerve · 2015 · 46 citations · 18 references
MedicineNeurologyOncologyNeuromuscular DisordersNeuropathologyPediatric NeurologyMotor NeuropathyNerve Conduction StudiesPediatric ElectrodiagnosisPediatric Neuro-oncologyPediatric NeuropathologyPeripheral NeuropathiesAntimitotic ActivityAntimitotic ChemotherapyAntimitotic DrugsAntimitotic TreatmentsAxonal PolyneuropathyDrug-induced Peripheral NeuropathyElectrophysiological RecordingsPediatric Peripheral Neuropathy
INTRODUCTION: Vincristine is an antimitotic agent used for treatment of leukemia, lymphomas, and cancers. Its main side effect is a dose-related, length-dependent (LD) axonal neuropathy. METHODS: We performed electrodiagnostic (EDx) examinations in 17 children who had been treated with vincristine and who presented with the clinical picture of a peripheral neuropathy. RESULTS: The mean dose of vincristine was 8.5 ± 4.0 mg/m(2) . Clinical motor symptoms were more frequent and more severe than sensory ones. Thirteen children presented with a motor deficit, 4 of whom could no longer walk. EDx examination showed an axonal neuropathy with a non-length-dependent (NLD) pattern in 9 children and an LD pattern in 8. A major motor predominance was encountered in 12 patients. CONCLUSIONS: The electrophysiological and clinical motor predominance described differs from the mainly sensory neuropathy reported in adults. Incomplete myelination due to young age may have resulted in greater sensitivity of some nerves to neurotoxic agents.
18
Vincristine‐induced neuropathy
S.G. Sandier, Wayne E. Tobin, Edward S. Henderson · Neurology · 1969 · 302 citations
The neuromyopathy of vincristine in man
Walter G. Bradley, L.P. Lassman, G. W. Pearce et al. · Journal of the Neurological Sciences · 1970 · 263 citations
Vincristine treatment of advanced cancer: a cooperative study of 392 cases.
James F. Holland, Carol Scharlau, Salman Gailani et al. · PubMed · 1973 · 236 citations
Medicine, Oncology, Pharmacology +12